Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2(V617F)) is found in approximately 50% of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Santos, Fabio P. S., Kantarjian, Hagop M., Jain, Nitin, Manshouri, Taghi, Thomas, Deborah A., Garcia-Manero, Guillermo, Kennedy, Debra, Estrov, Zeev, Cortes, Jorge, Verstovsek, Srdan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2010
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081385/
https://ncbi.nlm.nih.gov/pubmed/20008298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-10-246363
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller